Viventia Initiates Patient Treatment in Bladder Cancer Trial
Posted on: Tuesday, 3 April 2007, 12:00 CDT
Viventia Biotech has initiated patient treatment in its phase II clinical trial for Vicinium, for the treatment of locally persistent non-invasive bladder cancer.
Viventia's lead product, Proxinium, is being developed to treat late stage, locally advanced head and neck cancer and is currently enrolling patients in a phase III global trial that is also expected to complete accrual by the end of 2007. Vicinium and Proxinium are antibodies that target the cancer antigen EpCAM.
"The form of cancer we are treating, Tis bladder cancer, is frequently unresponsive following initial treatment and these patients usually require either partial or complete removal of the bladder to avoid metastasis to other organs," said Dr Nick Glover, president and CEO of Viventia Biotech.
"The goal of Vicinium treatment is to substantially reduce or eliminate the need for surgical resection or removal of the bladder. The potential of Vicinium was demonstrated in our previous trial, where an overall 95% response rate was observed."
The phase II clinical trial will enroll approximately 30 patients with locally persistent non-invasive Tis bladder cancer. Tis, or carcinoma in-situ of the urothelium, is a high-grade form of bladder cancer that behaves more aggressively than other forms of the disease.
Source: Datamonitor
Related Articles
- OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
- Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
- Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
- Ziopharm Initiates Phase II Liver Cancer Drug Trial
- Merck Starts Phase III Cancer Vaccine Trial
- Cell Therapeutics, Inc. (CTI) Closes PGT305 (PIONEER) Lung Cancer Clinical Trial; New PGT306 Protocol to Be Submitted to FDA By Year End
- Cell Therapeutics, Inc. (CTI) Temporarily Suspends Enrollment on PIONEER Lung Cancer Clinical Trial; Current Patients Continue to Be Treated
- Medivation Exceeds Patient Enrollment Target in Phase 2 Alzheimer's Disease Trial
- Pro-Pharmaceuticals Receives Clearance From EMEA to Initiate International Phase III Colorectal Cancer Clinical Trial
- Results of Phase IIa Study Show That Reverset Has Potential to Reduce HIV Viral Load in Treatment-Experienced Patients
 |
 |
User Comments (0)
RSS Feeds